Home > Healthcare > Pharmaceuticals > Finished Drug Form > Retinal Disorder Treatment Market

Retinal Disorder Treatment Market Share

Report ID: GMI10121
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Retinal Disorder Treatment Market Share

The retinal disorder treatment sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Retinal Disorder Treatment Market Companies

Some of the eminent market participants operating in the retinal disorder treatment industry include:

AbbVie Inc.
Alimera Sciences, Inc.
Alcon, Inc.
Bayer AG
Biogen Inc.
Bausch Health Companies
F. Hoffmann-La Roche Ltd.
Graybug Vision, Inc.
Merck & Co., Inc.
Novartis AG
Ophthotech Corporation
Pfizer, Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceuticals Co. Ltd.
Takeda Pharmaceutical Company Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Retinal disorder treatment industry size was worth USD 13.7 billion in 2023 and will grow at 9.6% CAGR between 2024 and 2032 due to the increasing prevalence of retinal diseases, such as diabetic retinopathy and age-related macular degeneration.

The eye drops segment registered USD 3.8 billion in 2023, driven by their non-invasive nature and ease of administration, making them a preferred choice among patients.

U.S. retinal disorder treatment industry will reach USD 11.4 billion by 2032, attributed to the advanced healthcare infrastructure and high prevalence of retinal diseases like age-related macular degeneration and diabetic retinopathy.

AbbVie Inc., Alimera Sciences, Inc., Alcon, Inc., Bayer AG, Biogen Inc., Bausch Health Companies, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Merck & Co., Inc., Novartis AG, Ophthotech Corporation, and Pfizer, Inc. among others.